Edward P. Monaghan
Director/Board Member at Lusaris Therapeutics, Inc.
Network origin in Edward P. Monaghan first degree
Entity | Entity type | Industry | |
---|---|---|---|
Lusaris Therapeutics, Inc.
Lusaris Therapeutics, Inc. BiotechnologyHealth Technology Lusaris Therapeutics, Inc. is a biotechnology company that focuses on developing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. The company is based in Boston, MA. The company's lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a rapidly acting and rapidly clearing serotonergic psychedelic, which is being developed to treat treatment-resistant depression and other neuropsychiatric conditions. The company's pipeline also includes novel neuroplastogens for a wide range of neuropsychiatric and neurological conditions, including migraine and cluster headache. The CEO of the company is Andrew D. Levin.
3
| Holding Company | Biotechnology | 3 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Edward P. Monaghan via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Clinton Group, Inc.
Clinton Group, Inc. Investment ManagersFinance Clinton Group, Inc. is a registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by George E. Hall in 1991 and is a subsidiary of Madison Avenue Capital Holdings, Inc., which is owned by CGI Holdings, Inc. Clinton Group serves as investment manager primarily for an offshore private investment fund, as well as pools of collateralized debt obligations (CDOs), collateralized bond obligations (CBOs) and other structured products for which the the firm as collateral manager. | Investment Managers | Corporate Officer/Principal | |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal | |
Tang Capital Management LLC
Tang Capital Management LLC Investment ManagersFinance Tang Capital Management LLC (Tang Capital) is an independent hedge fund manager headquartered in San Diego, California. The firm was founded by Kevin Tang in 2002. Tang Capital provides investment advice to high-net-worth clients. | Investment Managers | Analyst-Equity | |
Citadel Advisors LLC
Citadel Advisors LLC Investment ManagersFinance Citadel Advisors LLC is a SEC-registered investment advisor and hedge fund manager headquartered in Miami, Florida. The firm was founded in 1990 by Kenneth Griffin and is wholly-owned by Citadel Advisors Holdings LP, ultimately held by GFH HFEVA LLC. Citadel Advisors manages private investment funds that are offered exclusively to sophisticated investors. | Investment Managers | Analyst-Equity | |
RA Capital Management LP
RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities. | Investment Managers | Portfolio Manager-Equities | |
CONCERT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Cortria Corp.
Cortria Corp. Pharmaceuticals: MajorHealth Technology Cortria Corp. operates as a clinical-stage pharmaceutical company that focuses on developing medicines to fight cardiovascular disease. Its product is used for the treatment of dyslipidemia, an atherogenic disorder characterized by abnormal lipid levels in the bloodstream. The company was founded in August 2005 and is headquartered in Needham, MA. | Pharmaceuticals: Major | Chief Executive Officer | |
AbCellera Boston, Inc.
AbCellera Boston, Inc. BiotechnologyHealth Technology AbCellera Boston, Inc. produces vaccines for plant, animal, and human diseases. It focuses on the discovery of novel therapeutics for autoimmune disease and pain. The company was founded by Theodore G. Clark in 2004 and is headquartered in Arlington, MA. | Biotechnology | Director/Board Member | |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Biotechnology | Director/Board Member | |
H.I.G Capital LLC (Private Equity)
H.I.G Capital LLC (Private Equity) Investment ManagersFinance H.I.G. Capital LLC (H.I.G Capital) is a private equity division of H.I.G. Capital LLC founded in 1993 by Sami W Mnaymneh and Anthony A Tamer. The firm is headquartered in Miami, Florida with offices in Europe, Latin America and Middle East. | Investment Managers | Private Equity Investor | |
Massachusetts Institute of Technology | College/University | Doctorate Degree | |
Davidson College | College/University | Undergraduate Degree | |
Yale University | College/University | Graduate Degree | |
Princeton University | College/University | Undergraduate Degree | |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Pharmaceuticals: Major | President | |
Harvard Medical School | College/University | Doctorate Degree | |
H.I.G. BioHealth Partners LLC
H.I.G. BioHealth Partners LLC Investment ManagersFinance H.I.G. BioHealth Partners LLC (H.I.G. BioHealth Partners) is a private equity and venture capital subsidiary of H.I.G. Ventures LLC founded in 1993. The firm is headquartered in Miami, Florida with additional offices around the globe. | Investment Managers | Private Equity Investor | |
Clinton Health Access Initiative
Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services The Clinton Health Access Initiative (CHAI) is a health organization that is dedicated to saving lives, reducing the burden of disease, and strengthening health systems. CHAI is based in Boston, MA, and the CEO of the non-profit company is Deepak Verma. The organization's focus is on improving healthcare in developing countries. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
SYNTHORX, INC. | Biotechnology | Director/Board Member | |
ARVINAS, INC. | Biotechnology | Director/Board Member | |
Theriana Pharmaceuticals, Inc.
Theriana Pharmaceuticals, Inc. Drugstore ChainsRetail Trade Theriana Pharmaceuticals, Inc. provides pharmaceutical services. The company was founded in 2017 and is headquartered in Waltham, MA. | Drugstore Chains | Chief Executive Officer | |
Clear Creek Bio, Inc.
Clear Creek Bio, Inc. Pharmaceuticals: MajorHealth Technology Clear Creek Bio, Inc. engages in the development of therapies that target nucleotide synthesis pathways. The firm focuses on the differentiation blockade in cancer and suppress replication of RNA-based viruses. It uses pharmacodynamic markers to ensure that each patient gets the right drug at the correct dose. The company was founded by David T. Scadden, David B. Sykes, Burt A. Adelman, and Vikram Sheel Kumar in 2017 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Founder | |
ELIEM THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer | |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Investment Managers | Private Equity Investor | |
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Miscellaneous Commercial Services | Chief Executive Officer | |
Superluminal Medicines Inc
Superluminal Medicines Inc BiotechnologyHealth Technology Superluminal Medicines Inc is a generative biological and chemical company. The company is based in Boston, MA. The CEO of the company is Cony D'Cruz. | Biotechnology | Director/Board Member |
Statistics
International
United States | 32 |
United Kingdom | 2 |
Sectoral
Health Technology | 17 |
Finance | 10 |
Consumer Services | 5 |
Commercial Services | 3 |
Retail Trade | 2 |
Operational
Director/Board Member | 13 |
Chief Executive Officer | 6 |
President | 6 |
Corporate Officer/Principal | 4 |
Private Equity Investor | 3 |
Most connected contacts
Insiders | |
---|---|
Andrew Levin | 21 |
Daniel S. Grau | 13 |
Neil Buckley | 1 |
- Stock Market
- Insiders
- Edward P. Monaghan
- Company connections